FR08C0013I1 - - Google Patents

Info

Publication number
FR08C0013I1
FR08C0013I1 FR08C0013C FR08C0013I1 FR 08C0013 I1 FR08C0013 I1 FR 08C0013I1 FR 08C0013 C FR08C0013 C FR 08C0013C FR 08C0013 I1 FR08C0013 I1 FR 08C0013I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9911183.3A external-priority patent/GB9911183D0/en
Priority claimed from GBGB9911346.6A external-priority patent/GB9911346D0/en
Priority claimed from GBGB9918534.0A external-priority patent/GB9918534D0/en
Priority claimed from GBGB9927005.0A external-priority patent/GB9927005D0/en
Priority claimed from GBGB9927106.6A external-priority patent/GB9927106D0/en
Priority claimed from GB0007637A external-priority patent/GB0007637D0/en
Application filed filed Critical
Publication of FR08C0013I1 publication Critical patent/FR08C0013I1/fr
Application granted granted Critical
Publication of FR08C0013I2 publication Critical patent/FR08C0013I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
FR08C0013C 1999-05-13 2008-04-16 Utilisation de et743 en thérapie combinée avec dexaméthasone pour traiter le cancer Active FR08C0013I2 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB9911183.3A GB9911183D0 (en) 1999-05-13 1999-05-13 Treatment of cancers
GBGB9911346.6A GB9911346D0 (en) 1999-05-14 1999-05-14 Treatment of cancers
GBGB9918534.0A GB9918534D0 (en) 1999-08-05 1999-08-05 Treatment of cancers
GBGB9927005.0A GB9927005D0 (en) 1999-11-15 1999-11-15 Treatment of cancers
GBGB9927106.6A GB9927106D0 (en) 1999-11-16 1999-11-16 Cancer treatment
GB0007637A GB0007637D0 (en) 2000-03-29 2000-03-29 Antitumour compound
EP00927584A EP1176964B8 (en) 1999-05-13 2000-05-15 Uses of et743 for treating cancer

Publications (2)

Publication Number Publication Date
FR08C0013I1 true FR08C0013I1 (enExample) 2008-05-30
FR08C0013I2 FR08C0013I2 (fr) 2009-10-30

Family

ID=27546594

Family Applications (1)

Application Number Title Priority Date Filing Date
FR08C0013C Active FR08C0013I2 (fr) 1999-05-13 2008-04-16 Utilisation de et743 en thérapie combinée avec dexaméthasone pour traiter le cancer

Country Status (32)

Country Link
US (1) US8119638B2 (enExample)
EP (3) EP1702618B1 (enExample)
JP (2) JP2002544231A (enExample)
KR (1) KR20020019914A (enExample)
CN (2) CN1360503A (enExample)
AR (1) AR028476A1 (enExample)
AT (3) ATE500830T1 (enExample)
AU (2) AU777417B2 (enExample)
BG (1) BG65680B1 (enExample)
BR (1) BR0010531A (enExample)
CA (1) CA2373794C (enExample)
CY (4) CY1105818T1 (enExample)
CZ (1) CZ301482B6 (enExample)
DE (4) DE60045720D1 (enExample)
DK (3) DK1702618T3 (enExample)
ES (2) ES2272279T3 (enExample)
FR (1) FR08C0013I2 (enExample)
HU (2) HU229866B1 (enExample)
IL (2) IL146434A0 (enExample)
LU (1) LU91418I2 (enExample)
MX (1) MXPA01011562A (enExample)
MY (1) MY164077A (enExample)
NL (1) NL300337I2 (enExample)
NO (2) NO324564B1 (enExample)
NZ (1) NZ515423A (enExample)
PL (1) PL198185B1 (enExample)
PT (3) PT1176964E (enExample)
SI (3) SI1702618T1 (enExample)
SK (1) SK287580B6 (enExample)
TR (1) TR200103819T2 (enExample)
UA (1) UA74782C2 (enExample)
WO (1) WO2000069441A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
ATE495793T1 (de) * 2000-11-06 2011-02-15 Pharma Mar Sa Antitumorzusammensetzungen welche ecteinascidin 743 enthalten
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
HUP0401903A3 (en) * 2001-10-19 2008-07-28 Pharma Mar Improved use of et-743 in cancer thereapy
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
RS50692B (sr) * 2003-11-13 2010-06-30 Pharma Mar S.A.U. Kombinacija et-743 sa prolekovima 5-fluorouracila za lečenje kancera
JP2007511509A (ja) * 2003-11-14 2007-05-10 ファルマ・マール・ソシエダード・アノニマ Ｅｔ−７４３およびパクリタキセルの使用を含むガンの併用療法
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
EP1768671A2 (en) * 2004-07-09 2007-04-04 Pharma Mar, S.A. Use of ecteinascidin in the treatment of cancer in patients with low level of brca1
MX2007004744A (es) * 2004-10-26 2007-10-23 Pharma Mar Sa Doxorubicina lipos??mica pegilada en combinacion con ecteinascidina 743.
RS50510B (sr) * 2004-10-29 2010-03-02 Pharma Mar S.A., Sociedad Unipersonal Formulacije koje sadrže ekteinascidin i disaharid
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
JP2009536956A (ja) * 2006-05-12 2009-10-22 ファルマ・マール・ソシエダード・アノニマ 抗癌治療法
WO2009050303A1 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Prognostic molecular markers for et-743 treatment
BR112018015118A2 (pt) 2016-02-04 2018-12-18 Jiangsu Hengrui Medicine Co., Ltd. composição farmacêutica injetável inclusiva de trabectedina para uso externo gastrointestinal e método de fabricação da mesma
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
CN112574234B (zh) * 2019-09-27 2022-05-24 江苏恒瑞医药股份有限公司 一种海鞘素衍生物的制备方法
SI4041194T1 (sl) 2020-04-15 2024-10-30 Ever Valinject Gmbh Sestava, obsegajoča trabektedin in aminokislino
EP3960177A1 (en) * 2020-08-26 2022-03-02 Anturec Pharmaceuticals GmbH Composition comprising ttf-ngr for use in treating soft-tissue sarcoma
US12303506B2 (en) 2022-01-20 2025-05-20 Extrovis Ag Trabectedin composition

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5089273A (en) * 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
DE3774435D1 (de) * 1986-06-09 1991-12-12 Univ Pennsylvania Ekteinascidine 729, 743, 745, 759a, 759b and 770.
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
DE3635711A1 (de) * 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
GB8805268D0 (en) * 1988-03-04 1988-04-07 Glaxo Group Ltd Medicaments
GB9101221D0 (en) * 1991-01-19 1991-02-27 Smithkline Beecham Plc Pharmaceuticals
US5721352A (en) 1991-02-19 1998-02-24 University Of Florida Research Foundation Entomopoxvirus expression system
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5891704A (en) * 1992-11-19 1999-04-06 Anticancer, Inc. Method to produce high levels of methioninase
JPH09503743A (ja) * 1993-05-14 1997-04-15 デポテック コーポレーション 神経学的疾患の治療方法
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) * 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
GB9508195D0 (en) * 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
DE69734290T2 (de) * 1996-11-05 2006-07-06 The Children's Medical Center Corp., Boston Mittel zur hemmung von angiogenese enthaltend thalodomid und einen nsaid
IL123740A0 (en) * 1997-03-28 1998-10-30 Pfizer NK-1 receptor antagonists for the treatment of delayed emesis
US5985876A (en) * 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
DE19720312A1 (de) * 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
GB9801231D0 (en) * 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
DE69936845T2 (de) * 1998-04-06 2008-05-08 The Board Of Trustees Of The University Of Illinois, Urbana Halbsynthetische ectein-ascidine
ATE289810T1 (de) * 1998-05-11 2005-03-15 Pharma Mar Sa Ecteinascidinderivate
US6124292A (en) * 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MY130271A (en) * 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
KR100886496B1 (ko) 2000-04-12 2009-03-05 파르마 마르, 에스.에이. 항종양성 엑티나시딘 유도체
US7247892B2 (en) * 2000-04-24 2007-07-24 Taylor Geoff W Imaging array utilizing thyristor-based pixel elements
US7420051B2 (en) * 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
CA2418320A1 (en) * 2000-08-11 2002-02-21 City Of Hope The anti-neoplastic agent et-743 inhibits trans activation by sxr
ATE495793T1 (de) 2000-11-06 2011-02-15 Pharma Mar Sa Antitumorzusammensetzungen welche ecteinascidin 743 enthalten
EP1360337A1 (en) 2001-02-09 2003-11-12 The Regents Of The University Of California Ecteinascidin family compounds: compositions and methods
AU2002242561A1 (en) 2001-03-30 2002-10-15 Shire Biochem Inc. Methods of treating cancer using cyplastin combined with a dioxolane nucleoside such as troxacitabine
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
HUP0401903A3 (en) 2001-10-19 2008-07-28 Pharma Mar Improved use of et-743 in cancer thereapy
US20040019027A1 (en) * 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
RS50692B (sr) * 2003-11-13 2010-06-30 Pharma Mar S.A.U. Kombinacija et-743 sa prolekovima 5-fluorouracila za lečenje kancera
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
JP2007511509A (ja) * 2003-11-14 2007-05-10 ファルマ・マール・ソシエダード・アノニマ Ｅｔ−７４３およびパクリタキセルの使用を含むガンの併用療法
EP1768671A2 (en) * 2004-07-09 2007-04-04 Pharma Mar, S.A. Use of ecteinascidin in the treatment of cancer in patients with low level of brca1
WO2006035244A2 (en) 2004-09-29 2006-04-06 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti -inflammatory agents
MX2007004744A (es) * 2004-10-26 2007-10-23 Pharma Mar Sa Doxorubicina lipos??mica pegilada en combinacion con ecteinascidina 743.
RS50510B (sr) * 2004-10-29 2010-03-02 Pharma Mar S.A., Sociedad Unipersonal Formulacije koje sadrže ekteinascidin i disaharid
ES2361566T3 (es) * 2005-11-25 2011-06-20 Pharma Mar S.A., Sociedad Unipersonal Uso de inhibidores de parp-1.
JP2009536956A (ja) * 2006-05-12 2009-10-22 ファルマ・マール・ソシエダード・アノニマ 抗癌治療法

Also Published As

Publication number Publication date
PT1176964E (pt) 2007-01-31
SK16442001A3 (sk) 2002-03-05
AU2005200180B2 (en) 2007-12-13
PL198185B1 (pl) 2008-06-30
DE60045720D1 (de) 2011-04-21
EP1702618A2 (en) 2006-09-20
IL146434A (en) 2008-03-20
SK287580B6 (sk) 2011-03-04
ES2294756T3 (es) 2008-04-01
AU777417B2 (en) 2004-10-14
EP1176964B8 (en) 2007-10-10
HU229866B1 (en) 2014-10-28
CY1107143T1 (el) 2010-07-28
AU4597500A (en) 2000-12-05
CN1679631A (zh) 2005-10-12
LU91418I2 (fr) 2008-05-13
HUS1500001I1 (hu) 2016-08-29
AU2005200180A1 (en) 2005-02-10
DK1702618T3 (da) 2008-02-25
SI1176964T1 (sl) 2007-02-28
WO2000069441A1 (en) 2000-11-23
BG65680B1 (bg) 2009-06-30
ATE500830T1 (de) 2011-03-15
PL352931A1 (en) 2003-09-22
JP2002544231A (ja) 2002-12-24
DE60036826D1 (de) 2007-11-29
MY164077A (en) 2017-11-30
BR0010531A (pt) 2002-06-04
EP1716853B9 (en) 2011-09-28
DE60036826T2 (de) 2008-08-28
DE60030554T2 (de) 2007-09-13
CN1360503A (zh) 2002-07-24
CY1105818T1 (el) 2011-02-02
DK1176964T3 (da) 2007-01-15
EP1176964A1 (en) 2002-02-06
FR08C0013I2 (fr) 2009-10-30
NO2008005I1 (no) 2008-06-09
LU91418I9 (enExample) 2019-01-02
JP5777562B2 (ja) 2015-09-09
CY2008007I2 (el) 2009-11-04
CY2008007I1 (el) 2009-11-04
NO324564B1 (no) 2007-11-19
CN100477993C (zh) 2009-04-15
NZ515423A (en) 2004-04-30
HUP0201187A2 (en) 2002-09-28
CA2373794C (en) 2005-10-11
HUP0201187A3 (en) 2002-11-28
IL146434A0 (en) 2002-07-25
NL300337I1 (nl) 2008-05-01
PT1702618E (pt) 2008-01-11
EP1716853A2 (en) 2006-11-02
BG106171A (en) 2002-06-28
AR028476A1 (es) 2003-05-14
ES2272279T3 (es) 2007-05-01
EP1716853A3 (en) 2006-11-15
CA2373794A1 (en) 2000-11-23
NO2008005I2 (enExample) 2010-09-27
NL300337I2 (nl) 2008-09-01
MXPA01011562A (es) 2002-07-30
ATE375795T1 (de) 2007-11-15
UA74782C2 (uk) 2006-02-15
JP2012149095A (ja) 2012-08-09
EP1702618B1 (en) 2007-10-17
EP1716853B1 (en) 2011-03-09
DE122008000013I1 (de) 2008-08-07
ATE338552T1 (de) 2006-09-15
DE60030554T8 (de) 2008-01-10
SI1702618T1 (sl) 2008-02-29
DK1716853T3 (da) 2011-06-27
NO20015516L (no) 2002-01-11
DE60030554D1 (de) 2006-10-19
EP1702618A3 (en) 2006-12-27
SI1716853T1 (sl) 2011-10-28
US8119638B2 (en) 2012-02-21
TR200103819T2 (tr) 2002-04-22
PT1716853E (pt) 2011-05-12
CZ301482B6 (cs) 2010-03-17
CY1112753T1 (el) 2016-02-10
US20070275942A1 (en) 2007-11-29
CZ20014081A3 (cs) 2002-11-13
AU2005200180B9 (en) 2008-05-29
KR20020019914A (ko) 2002-03-13
EP1176964B1 (en) 2006-09-06
NO20015516D0 (no) 2001-11-12

Similar Documents

Publication Publication Date Title
BE2015C018I2 (enExample)
BE2014C017I2 (enExample)
BE2013C051I2 (enExample)
BE2013C020I2 (enExample)
BE2013C015I2 (enExample)
BE2008C046I2 (enExample)
BE1025464I2 (enExample)
JP2002509281A5 (enExample)
BE2008C047I2 (enExample)
JP2002525159A5 (enExample)
JP2002506701A5 (enExample)
JP2002526156A5 (enExample)
FR12C0014I1 (enExample)
FR08C0013I1 (enExample)
JP2002520860A5 (enExample)
JP2002533150A5 (enExample)
IN189919B (enExample)
JP2002521040A5 (enExample)
JP2002526286A5 (enExample)
JP2002530197A5 (enExample)
JP2002533847A5 (enExample)
HU0004454D0 (enExample)
JP2002530548A5 (enExample)
IN190453B (enExample)
IN191270B (enExample)